Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016280 | 0.99 | L3MBTL1 (0.36) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17016281 | 0.99 | L3MBTL1 (0.36) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17016277 | 0.99 | L3MBTL1 (0.38) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17016283 | 0.96 | L3MBTL1 (0.34) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL15989369 | 0.95 | L3MBTL1 (0.41) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17016127 | 0.95 | L3MBTL1 (0.41) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17016287 | 0.95 | L3MBTL1 (0.35) | KDM4EATML3MBTL1MAOBMAPK1 | |
| SCHEMBL16613847 | 0.95 | MAOB (0.37) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17016134 | 0.94 | L3MBTL1 (0.41) | KDM4EATML3MBTL1MAOBKDR | |
| SCHEMBL17015185 | 0.94 | L3MBTL1 (0.41) | KDM4EATML3MBTL1MAOBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | INMT, IDO1, IDO2 | KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.